Eli Lilly's Morphic acquisition brings an oral small molecule that blocks the same target as Entvyio, an injectable inflammatory bowel disease drug from Takeda Pharmaceutical. The Morphic deal follows Lilly's 2023 acquisition of Dice Therapeutics, another company developing oral immunology medications.
The 2024 Benefit Consultant Sentiment Index published by MedCity News and sponsored by Quantum Health, now in its second year, is based on a survey of more than 100 seasoned healthcare benefits consultants who represent a cross-section of employer size.
The report functions as an insider's guide to understanding how healthcare trends are shaping employer benefit decisions from the perspective of consultants.
Are you revolutionizing pediatric or teen health with your innovative solution?
Don't miss your chance to showcase your innovative startup at the INVEST Digital Health Pitch Perfect Contest at Pegasus Park on September 18 in Dallas!
Deadline for submissions is Wednesday July 10 at11:59pm ET.
Providence recently launched a study to help learn more about how health systems can use multi-cancer detection tests in clinical care. Three years ago, Providence became the first health system to use Grail's Galleri test, which screens patients for more than 50 kinds of cancer.
Several policy changes, including the Medicaid continuous enrollment provision and enhanced Marketplace tax credits, improved health coverage and access during Covid-19, a new report showed.
HilleVax's norovirus vaccine failed a Phase 2b study in infants, but it's not the end of the road for the biotech. A business deal this year brought HilleVax a Phase 1-ready norovirus vaccine candidate designed to offer even broader protection.
Rick Ratliff, a pharmacy industry veteran who was for a time CEO of Surescripts, built a national digital prescription network connecting doctors to pharmacies.
No comments